Últimas noticias sobre Spero Therapeutics (NASDAQ:SPRO) Bolsa

SPERO THERAPEUTICS INC

Spero Therapeutics

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics Inc

Sprott Active Gold & Silver Miners ETF

Sprott Copper Miners ETF

Sprott Critical Materials ETF

Sprott Focus Trust, Inc. - Closed End Fund

Sprott Focus Trust Inc

Sprott Gold Miners ETF

Sprott Inc

Sprott Junior Copper Miners ETF

Sprott Junior Gold Miners ETF

Sprott Junior Uranium Miners ETF

Sprott Lithium Miners ETF

Sprott Nickel Miners ETF

Sprott Physical Gold Trust

Sprott Physical Gold and Silver Trust Units

Sprott Physical Gold and Silver Trust

Sprott Physical Platinum and Palladium Trust

Sprott Physical Platinum & Palladium Tr

Sprott Physical Silver Trust

Sprott Physical Uranium Trust

Sprott Silver Miners & Physical Silver ETF

Sprott Uranium Miners ETF

Sprout AI Inc

Sprout Social, Inc - Class A Common Stock

Sprout Social Inc

SPROUT TINY HOMES by Sprout Tiny Homes, Inc.

Sprout Tiny Homes Inc

Sproutly Canada Inc

Sprouts Farmers Market, Inc. - Common Stock

Sprouts Farmers Market Inc

Earnings

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Spero Therapeutics to report an earnings per share (EPS) of $-0.26.
Anticipation surrounds Spero Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
Last quarter the company missed EPS by $0.07, which was followed by a 10.88% drop in the share price the next day.
Here's a look at Spero Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.31</td>
<td>-0.36</td>
<td>-0.38</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.38</td>
<td>-0.32</td>
<td>-0.33</td>
<td>-0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-6.0%</td>
<td>-5.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747080350_0.png" alt="eps graph" />
<h3>Tracking Spero Therapeutics's Stock Performance</h3>
Shares of Spero Therapeutics were trading at $0.62 as of May 09. Over the last 52-week period, shares are down 61.11%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SPRO/earnings">To track all earnings releases for Spero Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPRO

An Overview of Spero Therapeutics's Earnings

News

Management

Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer, Effective May 2

Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.31) by 22.58 percent. This is a 139.58 percent decrease over earnings of $0.96 per share from the same period last year. The company reported quarterly sales of $15.04 million which beat the analyst consensus estimate of $6.20 million by 142.65 percent. This is a 79.54 percent decrease over sales of $73.52 million the same period last year.

Earnings Beats

Earnings Misses

Spero Therapeutics Q4 EPS $(0.38) Misses $(0.31) Estimate, Sales $15.04M Beat $6.20M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. 
• Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) is projected to report quarterly loss at $1.40 per share on revenue of $2.90 million. 
• PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is projected to report earnings for its fourth quarter. 
• FitLife Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTLF#NASDAQ">FTLF</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $14.95 million. 
• ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is expected to report quarterly loss at $0.35 per share on revenue of $19.67 million. 
• Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is expected to report earnings for its fourth quarter. 
• Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is expected to report earnings for its fourth quarter. 
• Bitfarms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $53.82 million. 
• Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $608.95 million. 
• BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $16.80 million. 
• Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $20.83 million. 
• TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $8.24 million. 
• BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $2.29 million. 
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is expected to report quarterly loss at $0.07 per share on revenue of $1.07 million. 
• Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is likely to report earnings for its fourth quarter. 
• Ascentage Pharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) is projected to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONEK#NASDAQ">UONEK</a>) is estimated to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) is projected to report earnings for its fourth quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.91 per share on revenue of $14.79 billion. 
• Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly loss at $0.46 per share on revenue of $14.49 million. 
• Ermenegildo Zegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) is likely to report earnings for its Fiscal Year 2024. 
• Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is projected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $13.52 million. 
• Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) is projected to report earnings for its fourth quarter. 
• Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is projected to report quarterly loss at $0.66 per share on revenue of $1.45 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.85 million. 
• SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) is likely to report earnings for its fourth quarter. 
• INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is projected to report earnings for its fourth quarter. 
• TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) is estimated to report earnings for its fourth quarter. 
• Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is expected to report quarterly loss at $0.40 per share on revenue of $9.03 million. 
• IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is expected to report quarterly loss at $0.08 per share on revenue of $13.00 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is expected to report earnings for its fourth quarter. 
• TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) is expected to report earnings for its fourth quarter. 
• BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) is likely to report quarterly loss at $0.27 per share on revenue of $475 thousand. 
• Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly loss at $0.67 per share on revenue of $12.31 million. 
• Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) is expected to report earnings for its fourth quarter. 
• 374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) is likely to report quarterly loss at $0.02 per share on revenue of $100 thousand. 
• Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) is estimated to report earnings for its fourth quarter. 
• Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is projected to report quarterly loss at $0.95 per share on revenue of $920 thousand. 
• Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) is likely to report earnings for its fourth quarter. 
• BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter. 
• Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $0.51 per share on revenue of $1.19 million. 
• VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $8.09 million. 
• Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.37 million. 
• Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is likely to report quarterly loss at $0.31 per share on revenue of $6.20 million. 
• Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) is likely to report quarterly loss at $1.52 per share on revenue of $81.71 million. 
• Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) is expected to report earnings for its fourth quarter. 
• Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $19.48 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $12.80 million. 
• AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $679.95 million. 
• Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $383.94 million. 
• P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.17 per share on revenue of $385.80 million. 
• Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is likely to report quarterly loss at $0.34 per share on revenue of $375 thousand. 
• Argan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $212.05 million. 
• HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $9.30 million. 
• Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is expected to report quarterly earnings at $5.65 per share on revenue of $3.52 billion. 
• Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is likely to report quarterly loss at $0.11 per share on revenue of $294 thousand. 
• KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $2.87 million. 
• Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) is expected to report earnings for its fourth quarter. 
• Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) is expected to report quarterly loss at $0.06 per share on revenue of $4.15 million. 
• Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) is likely to report earnings for its fourth quarter. 
• Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $155.25 million. 
• Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is likely to report quarterly loss at $0.14 per share on revenue of $68.43 million. 
• Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is expected to report quarterly loss at $0.14 per share on revenue of $6.83 million. 
• Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.17 million. 
• Abacus Global Management (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $30.18 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPG

ADCT

BCAB

BITF

BKYI

The Beachbody Company, Inc. Class A Common Stock

BODI

BRFH

BRTX

BRZE

BTTR

BZAI

CLSD

CODX

DPRO

DRCT

EDAP

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FORA

FTLF

GOVX

ICCM

INMB

IPHA

JFIN

KULR

LTRN

LULU

LVLU

PDSB

PIII

PLSE

PSTV

RLMD

SACH

SCWO

SDST

SKYH

SSKN

TLSI

TSAT

TSSI

UMAC

UONE

UONEK

VTSI

WKSP

Earnings Scheduled For March 27, 2025

Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-03-27. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Spero Therapeutics will report an earnings per share (EPS) of $-0.31.
Spero Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.04, leading to a 5.6% drop in the share price the following trading session.
Here's a look at Spero Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.36</td>
<td>-0.38</td>
<td>-0.04</td>
<td>-0.10</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.32</td>
<td>-0.33</td>
<td>-0.24</td>
<td>0.96</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-5.0%</td>
<td>-3.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1743012116_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Spero Therapeutics were trading at $0.899 as of March 25. Over the last 52-week period, shares are down 48.83%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/SPRO/earnings">To track all earnings releases for Spero Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Spero Therapeutics's Earnings Potential

In the preceding three months, 4 analysts have released ratings for Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Spero Therapeutics and provided 12-month price targets. The average target is $5.0, accompanied by a high estimate of $5.00 and a low estimate of $5.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.09%. 
<img src="https://www.benzinga.com/files/images/story/2025/1738270812_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Spero Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Spero Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Spero Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Spero Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Spero Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SPRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Spero Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Spero Therapeutics</h2>
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
<h3>A Deep Dive into Spero Therapeutics's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Decline in Revenue: Over the 3 months period, Spero Therapeutics faced challenges, resulting in a decline of approximately -66.56% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Spero Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -219.3%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Spero Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -23.49%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Spero Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -12.03%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Spero Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.07.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) with a Buy and maintains $5 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $5 Price Target

These leadership changes were implemented as part of the Company's response to a "Wells Notice" from the Securities and Exchange Commission (the "SEC"), related to certain public disclosures by the Company from March 31, 2022 leading up to May 3, 2022. The Board's independent directors took these actions as a matter of corporate governance best practices and to enable the Company to maintain focus on pursuing its business objectives. The Board believes that the Company, Dr. Mahadevia and Mr. Shukla acted in good faith and consistent with their duties and obligations.

Biotech

Health Care

General

Spero Therapeutics Has Appointed Esther Rajavelu As Interim President And CEO, Stepping In For Sath Shukla, Who Has Agreed To A Voluntary Paid Administrative Leave For An Interim Period, The Board Has Also Appointed Director Frank Thomas As Chairman Of The Board, Stepping In For Dr. Ankit Mahadevia

During the last three months, 4 analysts shared their evaluations of Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.5, a high estimate of $7.00, and a low estimate of $5.00. Highlighting a 8.33% decrease, the current average has fallen from the previous average price target of $6.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1734696021_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Spero Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Schimmer</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Spero Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Spero Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Spero Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Spero Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SPRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Spero Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Spero Therapeutics's Background</h2>
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
<h3>Spero Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Challenges: Spero Therapeutics's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -66.56%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Spero Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -219.3%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Spero Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -23.49%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -12.03%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.07, Spero Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 4 Analyst Ratings Have To Say About Spero Therapeutics

Evercore ISI Group analyst Josh Schimmer downgrades Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) from Outperform to In-Line and maintains the price target from $5 to $5.

Downgrades

Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5

TD Cowen analyst Ritu Baral downgrades Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) from Buy to Hold.

TD Cowen Downgrades Spero Therapeutics to Hold

Cantor Fitzgerald analyst Louise Chen reiterates Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics

Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.36) by 11.11 percent. The company reported quarterly sales of $13.469 million which beat the analyst consensus estimate of $7.667 million by 75.68 percent. This is a 47.12 percent decrease over sales of $25.473 million the same period last year.

Spero Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.36) Estimate, Sales $13.469M Beat $7.667M Estimate

AFMD

Earnings Scheduled For November 14, 2024

Comments

Spero Therapeutics

Noticias

Últimas noticias sobre Spero Therapeutics (NASDAQ:SPRO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL